

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/573,850  
 Filing Date 03-29-06  
 First Named Inventor Kazutaka Nakamoto  
 Art Unit 1625  
 Examiner Name Patricia L. Morris  
 Attorney Docket Number 3939-0118PUS1

Sheet 1 of 3

**U.S. PATENT DOCUMENTS**

Examiner Initial *	Cite No. 1	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code 2 (if known)			
	1	US-2004-0198773		10-07-2004	Hart et al.	
	2	US-2005-0119229		06-02-2005	Ammermann et al.	
	3	US-2006-0270637		11-30-2006	Gravestock et al.	
	4	US-2007-0157463		07-19-2007	Sankaranarayanan	
	5	US-5,371,086		12-06-1994	Takemoto et al.	
	6	US-5,891,130		11-25-1997	Lupold et al.	
	7	US-5,891,338		11-25-1997	Dorn et al.	
	8	US-6,235,728		05-22-2001	Golik et al.	
	9	US-6,414,013		07-02-2002	Facelli et al.	
	10	US-7,179,804		02-20-2007	Amegadzie et al.	
	11	US-7,179,822		02-20-2007	Bunker et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initial *	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	T/S
		Country Code	Number/Kind Code (if known) 3				
	12	EP	0 124 154	11-07-1984			
	13	WO	03-091226	11-06-2003			
	14	WO	03-091227	11-06-2003			
	15	JP	2001-027063	12-25-2001			X
	16	WO	2004-014365	02-19-2004			
	17	JP	2005-026751	09-08-2006			X
	18	JP	2005-019247	08-24-2006			X
	19	WO	2009-084621	07-09-2009			X
	20	JP	5-094935	11-09-1993			X
	21	JP	55-073575	04-25-1984			X

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

\* EXAMINER: Initial 1 reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Completed. Include on this form with next communication to applicant.

1. Applicant's unique citation designation number (optional) 2. See Kind Code of USPTO Patent Documents, at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.  
 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.4). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
 SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	10/573,890
Filing Date	03-29-06
First Named Inventor	Kazutaka Nakamochi
Art Unit	1625
Examiner Name	Patricia L. Morris
Attorney Docket Number	3939-0118PUS1

(Use as many sheets as necessary)

Sheet	2	of	3
-------	---	----	---

[illegible]

Examiner Initials *	Class No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	78
		Country Code	Number and Class (if known)				
	22	JP	8-175083	07-09-1996			X

Date  
Considered

\* EXAMINER: Initial if a former considered, whether or not citation is in conformance with MDEP 606. Draw line through citation if not in conformance and not

Considered: Include up line form with next communication to applicant.

1. Applicant's priority citation designation number (optional) 2. See Kind codes of USPTO patent Documents, at [www.uspto.gov](http://www.uspto.gov) or MPEP 901:04.

3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1.

116. A comment is to make a check mark next to English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to examine) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.44. This collection is exempted to this 2 have to complete including authors

In general, an application for continuance is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. The duration is estimated to take 2 hours to complete, prepare, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the above

to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer.

to complete this form, and/or suggestions for reducing this burden, should be sent to: E.O. Rev. 1417, Alexandria, VA 22313-1420. DO NOT SEND HERE OR COMPLETED

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PLM/ (07/29/2010)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **3** of **3**

## **Complete if Known**

Application Number	10/573,890
Filing Date	03-29-06
First Named Inventor	Kazutaka Nakamoto
Group Art Unit	
Examiner Name	
Attorney Docket Number	3539-0118FUS1

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	Y 2
	23	CHANG et al., "Synthesis and Structure-Activity Relationships of Quaternary Ammonium Cephalosporins with 3-Pyrazolopyridinium Derivatives," Bioorganic & Medicinal Chemistry Letters (Exp. Opin. Ther. Patents, Vol. 5, No. 9, 1995, pp. 1211-1214	
	24	CONNORS et al., "Prodrugs in medicine," Overview, Biologicals & Immunologicals, Exp. Opin. Ther. Patents, Vol. 5, No. 9, 1995, pp. 873-885	
	25	Copy of an Office Action from co-pending U.S. Patent Application No. 11/589,126, mailed May 7, 2009	
	26	HATA, "New Approaches to Antifungal Drugs for the Treatment of Fungal and Protozoal Infections, Ravuonazole and Beyond: New Targets and Pro-clinical Strategies," The SMI's 12th Annual Conference, Superbugs and Superdrugs, March 18, 2010, Crowne Plaza London - St. James, 44 pages	
	27	International Search Report dated May 20, 2008 for corresponding International Application No. PCT/JP2008/057851	
	28	ISHIKAWA et al., "TAK-559, a Novel N-Phosphono Type Prodrug of Anti-MRSA Cephalosporin T-91825: Synthesis, Physicochemical and Pharmacological Properties," Bioorganic & Medicinal Chemistry, Vol. 11, pp. 2427-2437, (2003)	
	29	LUKEVICS et al., "Synthesis and cytotoxicity of silyl- and carbonyl-substituted isoxazoles," Chemistry of Heterocyclic Compounds (2000) Vol. 36, No. 10, pp. 1226-1231	
	30	PLATE et al., "Synthesis and Muscarinic Activities of 3-(Pyrazolyl)-1,2,5,6-tetrahydropyridine Derivatives," Bioorganic & Medicinal Chemistry Letters (1999) Vol. 4, No. 2, pp. 227-237	
	31	Supplementary European Search Report dated February 6, 2009 for corresponding European Application No. 04786159.4	
	32	TAJAKA et al., "An Effective Lewis Acid-Mediated 1,3-Dipolar Cycloaddition of Nitrile Oxide Using Acrylonitrile: Synthesis of a (2-Pyrazolopyridin-3-yl)isoxazole Derivative and its Application to Novel Antifungal Agents," pp. 1-8	
	33	VRZESCHCH et al., "Supercoperativity in platelet aggregation: Substituted pyridyl isoxazoles, a new class of supercooperative platelet aggregation inhibitors," FEBS Letters (1994) Vol. 351, No. 2, pp. 158-170	

Examiner Signature	/Patricia L. Morris/ (07/29/2010)	Date Considered
--------------------	-----------------------------------	-----------------

\* EXAMINER: Initial reference considered, whether or not citation is in compliance with MPEP 808. Draw line through citation if not in compliance and not considered. Include only of this item with need communication to applicant.

1. Applicant's unique citation designation number, optional 2. Applicant is to place a check mark here if English language translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO in process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, reviewing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form under suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FILES OR COMPLETED FORMS TO THIS ADDRESS.  
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.